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Combination therapy may be required for multidrug-resistant (MDR) Pseudomonas aeruginosa. The aim of
this study was to systematically investigate bacterial killing and emergence of colistin resistance with colistin
and doripenem combinations against MDR P. aeruginosa. Studies were conducted in a one-compartment in
vitro pharmacokinetic/pharmacodynamic model for 96 h at two inocula (106 and 108 CFU/ml) against a
colistin-heteroresistant reference strain (ATCC 27853) and a colistin-resistant MDR clinical isolate (19147
n/m). Four combinations utilizing clinically achievable concentrations were investigated. Microbiological
response was examined by log changes and population analysis profiles. Colistin (constant concentrations of
0.5 or 2 mg/liter) plus doripenem (peaks of 2.5 or 25 mg/liter every 8 h; half-life, 1.5 h) substantially increased
bacterial killing against both strains at the low inoculum, while combinations containing colistin at 2 mg/liter
increased activity against ATCC 27853 at the high inoculum; only colistin at 0.5 mg/liter plus doripenem at 2.5
mg/liter failed to improve activity against 19147 n/m at the high inoculum. Combinations were additive or
synergistic against ATCC 27853 in 16 and 11 of 20 cases (4 combinations across 5 sample points) at the 106-
and 108-CFU/ml inocula, respectively; the corresponding values for 19147 n/m were 16 and 9. Combinations
containing doripenem at 25 mg/liter resulted in eradication of 19147 n/m at the low inoculum and substantial
reductions in regrowth (including to below the limit of detection at 50 h) at the high inoculum. Emergence
of colistin-resistant subpopulations of ATCC 27853 was substantially reduced and delayed with combina-
tion therapy. This investigation provides important information for optimization of colistin-doripenem
combinations.
Multidrug-resistant (MDR) Pseudomonas aeruginosa is one
of several important Gram-negative bacteria emerging as sig-
nificant pathogens worldwide (8, 50). With a very limited num-
ber of therapeutic options against these pathogens remaining
and a lack of novel antimicrobial agents in the drug develop-
ment pipeline (30, 50), particularly those with activity against
P. aeruginosa (50), clinicians have been forced to reexamine
the use of “old,” previously discarded drugs such as the poly-
myxins (8, 40). Colistin (also known as polymyxin E) is a
multicomponent cationic polypeptide antibiotic largely aban-
doned in the 1970s due to concerns about the potential for
nephro- and neurotoxicity (15, 27). Colistin retains significant
in vitro activity against Gram-negative “superbugs” and is often
the only therapeutic option available to treat infections caused
by these pathogens (1, 27, 35). Several institutions have already
experienced outbreaks of infections with MDR Gram-negative
bacteria resistant to all commercially available antibiotics ex-
cept the polymyxins (6, 26, 34). Of particular concern is that
with the rapid increase in the use of colistin over the last
decade, especially for critically ill patients (8, 27), has come an
increase in the number of reports of resistance to colistin (1,
23, 27).
Having entered clinical use in 1959, colistin was never sub-
jected to the scientific rigor required for modern pharmaceu-
ticals before they become available for use in patients. The
result has been a dearth of reliable information on pharmaco-
kinetics (PK) and pharmacodynamics (PD) with which to guide
therapy, and confusion has surrounded the optimal dosing
strategy. It is only very recently that crucial gaps in our knowl-
edge of the PK and PD of colistin have begun to be filled.
Recent investigations into the PK of colistin in critically ill
patients have revealed low and potentially suboptimal plasma
drug concentrations in a substantial proportion of patients
receiving currently recommended dosage regimens (16, 47). In
addition, both in vitro (3, 4, 48, 52) and in vivo (22, 32) studies
have shown the potential for the rapid emergence of colistin
resistance with monotherapy, with heteroresistance a likely
contributing factor; colistin heteroresistance has been identi-
fied in Acinetobacter baumannii (28, 55), Klebsiella pneumoniae
(48, 53), and most recently in P. aeruginosa (5a). The potential
presence of colistin-resistant subpopulations of heteroresistant
strains prior to therapy and the observation of rapid amplifi-
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cation of colistin-resistant subpopulations with colistin mono-
therapy suggest caution with the use of colistin monotherapy
and highlight the importance of investigating rational and
novel colistin combinations. The aim of the present study was
to systematically investigate the extent of in vitro bacterial
killing and the emergence of colistin resistance with colistin
alone and in combination with doripenem at both high and low
inocula of P. aeruginosa using clinically relevant dosage regi-
mens. This was achieved by simulating, in an in vitro PK/PD
model, the PK of colistin formation and doripenem in humans
over a range of clinically achievable concentrations in critically
ill patients.
(Parts of this study were presented at the 50th Interscience
Conference on Antimicrobial Agents and Chemotherapy
[ICAAC], Boston, MA, 12 to 15 September 2010.)
MATERIALS AND METHODS
Bacterial isolates. Two strains of P. aeruginosa were employed in this study: a
colistin-heteroresistant reference strain, ATCC 27853 (American Type Culture
Collection, Rockville, MD), and a nonmucoid colistin-resistant MDR clinical
isolate, 19147 n/m, obtained from a patient with cystic fibrosis; the clinical isolate
contained genes encoding IMP-type carbapenemase and CTX-M-type extended-
spectrum -lactamase (ESBL). Heteroresistance to colistin was defined as
the ability of subpopulations of a strain to grow in the presence of 2 mg/liter in
the population analysis profiles (PAPs; see below) although the colistin MIC for
the strain was 2 mg/liter. MDR was defined as diminished susceptibility to
2-mg/liter concentrations of drugs from the following five classes: antipseudo-
monal cephalosporins, antipseudomonal carbapenems, -lactam–-lactamase in-
hibitor combinations, antipseudomonal fluoroquinolones, and aminoglycosides
(45). MICs of colistin (sulfate) and doripenem were each 1 mg/liter for ATCC
27853 and were 128 and 0.25 mg/liter for 19147 n/m, respectively. MICs of
colistin and doripenem for each isolate were determined in three replicates on
separate days in cation-adjusted Mueller-Hinton broth (CAMHB; Ca2 at 23.0
g/ml, Mg2 at 12.2 g/ml [Oxoid, Hampshire, England]) via broth microdilu-
tion (13). Resistance to colistin (13) and doripenem (42) was defined as MICs of
4 mg/liter. Strains were stored in tryptone soy broth (Oxoid, Basingstoke,
Hampshire, England) with 20% glycerol (Ajax Finechem, Seven Hills, New
South Wales, Australia) at80°C in cryovials (Simport Plastics, Beloeil, Quebec,
Canada).
Antibiotics and reagents. For MIC determinations and in vitro PK/PD studies,
colistin sulfate (lot 109K1574; 23,251 U/mg) was purchased from Sigma-Aldrich
(St. Louis, MO), while doripenem (lot 0137Y01) was kindly donated by Johnson
and Johnson (Shionogi and Co., Osaka, Japan). Colistin sulfate was used in the
present study as colistin is the active antibacterial agent formed in vivo after
administration of its inactive prodrug, colistin methanesulfonate (CMS) (5).
Stock solutions of doripenem were prepared using Milli-Q water (Millipore
Australia, North Ryde, New South Wales, Australia) immediately prior to each
dose, protected from light to minimize loss from degradation, and sterilized by
filtration with a 0.22-m-pore-size Millex-GP filter (Millipore, Bedford, MA).
Colistin was similarly prepared at the beginning of each experiment and spiked
into the growth medium of the central reservoir (see below) to achieve the
desired concentration; preliminary experiments demonstrated that colistin was
stable under these conditions for the duration of the experiment. All other
chemicals were from suppliers listed previously (24).
Binding of doripenem in growth medium. The binding of doripenem in
CAMHB was measured by equilibrium dialysis using Dianorm equilibrium dia-
lyzer units containing two chambers (with a 1-ml volume in each chamber)
separated by a semipermeable membrane (regenerated cellulose membrane;
molecular mass cutoff, 10,000 Da [Harvard Apparatus, Holliston, MA]). Dorip-
enem was spiked into CAMHB (in the donor chamber) to achieve a concentra-
tion of 25 mg/liter and dialyzed at 37°C against the same volume of isotonic
phosphate buffer, pH 7.4 (in the acceptor chamber); samples were prepared in
triplicate. Samples of CAMHB and buffer were removed from each reservoir
after 4 h (shown in preliminary studies to be the time required for equilibration)
and stored at 80°C until being analyzed as described below. The fraction of
doripenem unbound in CAMHB (ƒu) was calculated as follows: (acceptor dorip-
enem concentration)/(donor doripenem concentration).
In vitro PK/PD model and colistin-doripenem dosing regimens. Experiments
to examine the microbiological response and emergence of resistance to various
dosage regimens of colistin and doripenem alone and in combination were
conducted over 96 h at two different starting inocula (106 and 108 CFU/ml)
using a one-compartment in vitro PK/PD model described previously (4) and
below. Prior to each experiment, strains were subcultured onto horse blood agar
(Media Preparation Unit, The University of Melbourne, Parkville, Australia)
and incubated at 35°C for 24 h. One colony was then selected and grown
overnight in 10 ml of CAMHB, from which early-log-phase growth was obtained.
For a starting inoculum of 106 CFU/ml, a 1.0-ml aliquot of this early-log-phase
bacterial suspension was inoculated into each compartment at the commence-
ment of the experiment to yield106 CFU/ml. To achieve a starting inoculum of
108 CFU/ml, the flow of medium was temporarily halted, a 1.0-ml aliquot of
overnight culture was inoculated into each compartment on the morning of the
experiment, and the bacteria were allowed to grow until 108 CFU/ml was ob-
tained. The experiment was commenced immediately upon attainment of 108
CFU/ml.
The PK/PD model consisted of eight sealed containers (compartments) each
containing 80 ml of CAMHB at 37°C and a magnetic stir bar to ensure adequate
mixing. One compartment acted as a control to define growth dynamics in the
absence of antibiotic, while colistin and/or doripenem was delivered into the
remaining compartments to achieve the desired constant concentration (for
colistin) or intermittent (doripenem) dosage regimen (see below). A peristaltic
pump (Masterflex L/S; Cole-Parmer) was used to deliver sterile CAMHB from
separate central reservoirs into each compartment at a predetermined rate,
displacing an equal volume of CAMHB into a waste receptacle. Flow rates were
calibrated prior to each experiment and monitored throughout to ensure that the
system was performing optimally. For colistin-containing regimens, colistin was
delivered as a constant concentration by spiking colistin into the central reservoir
prior to initiation of the experiment so that all media flowing through the system
(with the exception of that in the growth control compartment) contained a
constant concentration of colistin (Table 1); colistin was administered in this way
to mimic the flat plasma drug concentration-time profiles of formed colistin at
steady state observed in critically ill patients given CMS (16, 47). For colistin-
containing regimens at the higher inoculum (108 CFU/ml), each compartment
was initially filled with sterile drug-free CAMHB to allow bacterial growth up to
108 CFU/ml in the absence of the drug; subsequently, a loading dose of colistin
was administered to immediately attain the targeted colistin concentration. For
doripenem-containing regimens, doripenem was injected into each treatment
compartment following bacterial inoculation to achieve the desired steady-state
maximum (peak) concentration (Cmax), with intermittent 8-hourly dosing there-
after (Table 1); as doripenem does not accumulate following multiple intrave-
nous (i.v.) administrations, no loading dose was required to achieve steady-state
concentrations. The chosen flow rate simulated a doripenem elimination half-life
(t1/2) of 1.5 h, which approximates that in critically ill patients (33).
Three constant concentrations of colistin and three intermittent doripenem
dosage regimens were simulated for monotherapy (Table 1). For combination
therapy against both isolates, colistin at a constant concentration of 0.5 or 2.0
mg/liter was used in combination with intermittent doripenem at a concentration
of 2.5 or 25 mg/liter, yielding four combination regimens (Table 1); combination
dosage regimens mimicked the PK profiles of each drug achieved in critically ill
patients (16, 31, 47). As we have demonstrated previously that colistin (3) and in
the present study doripenem are almost entirely unbound in CAMHB, the
specified concentrations represent unbound (free) concentrations.
Microbiological response and emergence of resistance to colistin. Serial sam-
ples (0.6 ml) were collected aseptically at the times shown in Table 1 from each
reservoir for viable-cell counting and real-time PAPs, as well as determination of
colistin and doripenem concentrations. Viable-cell counts and PAPs were ob-
tained immediately after sampling by using a WASP 2 spiral plater (Don Whitley
Scientific Ltd., United Kingdom) to plate 50 l of a sample appropriately diluted
(using 0.9% saline) onto either nutrient agar (for viable-cell counting) or Mu-
eller-Hinton agar (for PAPs) and incubating the plates at 35°C for 24 h (48 h for
plates with small colonies). Serial dilution and plating with the spiral plater,
which further dilutes the sample, helped reduce the possibility of antibiotic
carryover. PAP plates were impregnated with colistin (sulfate) at 0, 0.5, 1, 2, 3,
4, 5, 6, 8, and 10 mg/liter; these concentrations were chosen after consideration
of the MICs and the colistin concentrations typically achievable in plasma after
intravenous CMS administration to patients (16, 31, 47). Full PAPs incorporating
all colistin concentrations were determined at 0 and 96 h; mini-PAPs (for 0, 2, 4,
and 8 mg/liter) were determined at 6, 24, 48, and 72 h. Colonies were counted
using a ProtoCOL colony counter (Don Whitley Scientific Ltd., United King-
dom); the limit of detection was 20 CFU/ml (equivalent to 1 colony per plate),
and the limit of quantification was 400 CFU/ml (equivalent to 20 colonies per
plate), as specified in the ProtoCOL manual.
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PK validation. Samples (100 l) collected in duplicate from the in vitro PK/PD
experiments were placed in 1.50-ml microcentrifuge tubes (Greiner Bio-One,
Frickenhausen, Germany) and immediately stored at 80°C until analysis; all
samples were assayed within 4 weeks. Concentrations of colistin were measured
using high-performance liquid chromatography (HPLC) (25) with an assay range
for colistin sulfate of 0.10 to 6.00 mg/liter. Doripenem concentrations were
assayed at ambient temperature using a validated reversed-phase HPLC method.
The HPLC system consisted of a Shimadzu LC-20AD Prominence liquid chro-
matograph, a SIL-20AC HT Prominence autosampler, and an SPD-M20A Prom-
inence diode array detector (Shimadzu, Columbia, MD). To a 100-l sample, 100
l of 3-(N-morpholino)propanesulfonic acid (MOPS) buffer and 400 l of meth-
anol were added, and the mixture was subjected to a vortex and centrifuged at
10,000 rpm for 10 min. An aliquot of the sample (50 l) was injected onto a
PhenoSphere-NEXT 5-m C18 column (250 by 4.6 mm; Phenomenex, Torrance,
CA). A gradient elution procedure involving 100% methanol and 0.1% trifluo-
roacetic acid as the mobile phases was used, the proportion of methanol increas-
ing from 5 to 80% over 4 min and then returning to 5% over 0.5 min; the flow
rate was 0.7 ml/min, with detection at 311 nm. The run time was 10 min. The
assay range for doripenem was 0.5 to 32 mg/liter; samples were diluted when the
expected doripenem concentrations were higher than the upper limit of quanti-
fication. Analysis of quality control (QC) samples with nominal concentrations of
0.40 and 4.0 mg/liter for colistin and 1.2, 12, and 48 mg/liter for doripenem (the
latter QC sample requiring dilution) demonstrated accuracy of 90% and co-
efficients of variation of 10.2% for both colistin and doripenem.
PD analysis. Microbiological responses to monotherapy and combination
therapy were examined using the log change method, calculating the change in
log10 CFU per milliliter from 0 h (CFU0) to time t (6, 24, 48, 72 or 96 h; CFUt)
as shown: log change  log10(CFUt)  log10(CFU0).
Single-antibiotic or combination regimens causing a reduction of 1 log10
CFU/ml below the initial inoculum at 6, 24, 48, 72, or 96 h were considered
active. We considered synergy to be a 2-log10-lower number of CFU per
milliliter for the combination than for its most active component at the specified
time (46); additivity was defined as a 1- to 2-log10-lower number of CFU per
milliliter for the combination.
RESULTS
PK validation and doripenem binding. The colistin drug
concentrations achieved (means 	 standard deviations [SD])
were 0.45 	 0.07 mg/liter (n  22), 1.76 	 0.17 mg/liter (n 
26), and 4.58 	 0.02 mg/liter (n  6) for the targeted
concentrations of 0.5, 2.0, and 5.0 mg/liter, respectively.
Measured doripenem Cmax and minimum (trough) concen-
tration (Cmin) values were 51.47 	 3.96 mg/liter (n  30)
and 1.24 	 0.42 mg/liter (n  30) for the targeted values of
50.0 and 1.24 mg/liter and 25.60 	 2.53 mg/liter (n  50) and
0.80 	 0.26 mg/liter (n  50) for the targeted values of 25.0
and 0.62 mg/liter. For the targeted doripenem Cmax of 2.5
mg/liter, the measured Cmax was 2.45	 0.32 mg/liter (n 50),
with all Cmin values below the limit of quantification (0.5 mg/
liter) of the HPLC assay. Typical simulated PK profiles for
doripenem dosage regimens of 25 and 50 mg/liter every 8 h are
shown in Fig. 1. The observed mean t1/2 for the simulated
intermittent doripenem dosage regimens was 1.55 	 0.17 h
(n  71) for the targeted value of 1.5 h; as the Cmin for some
dosage regimens was below the lower limit of quantification of
the HPLC assay, t1/2 was not directly measured in all experi-
ments. The ƒu at equilibrium was 0.95, indicating practical
equivalence of total and unbound concentrations.
Microbiological response. The initial inocula (means 	 SD)
were 6.20 	 0.10 log10 CFU/ml (n  11) and 8.09 	 0.08 log10
CFU/ml (n  11) for ATCC 27853 and 6.30 	 0.16 log10
TABLE 1. Colistin and doripenem dosage regimens, PK/PD index values, and sampling times in the in vitro PK/PD modela
Treatment regimen Target Cmax/Cmin(mg/liter)
Valuee for ATCC 27853/isolate 19147 n/m Sampling times (h) for microbiological
measurementsfAUC/MIC Cmax/MIC %TMIC
Col monotherapyb 0.5 12.0/0.09 0.5/0.004 0/0 0, 1, 2, 3, 4, 6, 23, 24, 25, 26, 47, 48, 49, 50,
71, 72, 73, 74, 95, 962.0 48.0/0.38 2.0/0.02 100/0
5.0 120/0.94 5.0/0.04 100/0
Dor monotherapyc 2.5/0.062 15.8/63.3 2.5/10 24.8/62.3 0, 1, 2, 3, 4, 6, 23, 24, 25, 26, 30, 47, 48, 49,
50, 54, 71, 72, 73, 74, 78, 95, 9625/0.62 158/633 25/100 87.1/100
50/1.24 317/1,266 50/200 100/100
Combination therapyd 0, 1, 2, 3, 4, 6, 8, 23, 24, 25, 26, 29, 32, 47, 48,
49, 50, 53, 56, 71, 72, 73, 74, 77, 80, 95, 96
a Dosage regimens were tested with 106 and 108 CFU/ml starting inocula.
b Colistin (Col) dosage regimens involved a constant concentration of colistin simulating continuous infusion. For the colistin-resistant isolate (19147 n/m), only
colistin at 5.0 mg/liter was used as monotherapy. Values shown for isolate 19147 n/m at other dosages of colistin are those for combination therapy with the indicated
concentration of colistin.
c Doripenem (Dor) dosage regimens involved intermittent administration (every 8 h) to achieve the targeted Cmax/Cmin.
d Combination therapy was carried out with the following concentrations: colistin at 0.5 mg/liter plus doripenem at 2.5 mg/liter, colistin at 0.5 mg/liter plus doripenem
at 25 mg/liter, colistin at 2.0 mg/liter plus doripenem at 2.5 mg/liter, and colistin at 2.0 mg/liter plus doripenem at 25 mg/liter.
e Values shown are target values for PK/PD indices. For combination therapy, the PK/PD indices for each drug were the same as those for equivalent monotherapy.
AUC/MIC, area under the concentration-time curve over 24 h in the steady state divided by the MIC; %TMIC, cumulative percentage of a 24-h period that the drug
concentration exceeds the MIC under steady-state PK conditions.
f The number of CFU per milliliter was determined at all time points. Full PAPs were generated at 0 and 96 h; mini-PAPs were generated at 6, 24, 48, and 72 h.
FIG. 1. Targeted doripenem (Dor) PK profiles for 25- and 50-mg/
liter 8-hourly regimens with measured Dor concentrations.
VOL. 55, 2011 COLISTIN AND DORIPENEM AGAINST P. AERUGINOSA 5687
 o
n
 N
ovem
ber 4, 2015 by University of Queensland Library
http://aac.asm
.org/
D
ow
nloaded from
 
CFU/ml (n  9) and 7.88 	 0.28 log10 CFU/ml (n  9) for
19147 n/m for the targets of 106 and 108 CFU/ml, respectively.
The time course profiles of bacterial numbers achieved with all
dosage regimens at both inocula are shown in Fig. 2 (for ATCC
27853) and Fig. 3 (for 19147 n/m). Log changes in viable-cell
counts at each inoculum with mono- and combination therapy
are presented in Table 2.
Colistin monotherapy. With ATCC 27853 at the 106-
CFU/ml inoculum, colistin monotherapy produced rapid and
extensive initial killing at all concentrations, with colistin at 2
and 5 mg/liter resulting in undetectable bacterial counts at 2 h
(Fig. 2A). Substantial regrowth was evident at 6 h with colistin
at 0.5 mg/liter and at 24 h with colistin at 2 mg/liter, with
regrowth approaching that of the control by 24 h (for 0.5
mg/liter) and 72 h (for 2 mg/liter). No viable colonies were
detected until 54 h with colistin at 5 mg/liter, with subsequent
regrowth to 4 log10 CFU/ml observed at 96 h. An inoculum
effect with colistin monotherapy was observed, with substan-
tially reduced initial bacterial killing at the high compared to
the low inoculum with colistin at 0.5 and 2 mg/liter (Fig. 2D).
While rapid and extensive initial bacterial killing to below the
limit of detection remained at the high inoculum with colistin
at 5 mg/liter, substantial regrowth (to 3.5 log10 CFU/ml) had
occurred by 6 h, with regrowth to above the level of the initial
FIG. 2. Time-kill curves for colistin monotherapy (A and D), doripenem monotherapy (B and E), and combination therapy (C and F) against
ATCC 27853 at the 106-CFU/ml inoculum (left panels) and the 108-CFU/ml inoculum (right panels). The y axis starts from the limit of detection,
and the limit of quantification (LOQ) is indicated by the horizontal broken line.
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inoculum by 30 h. For the colistin-resistant isolate, bacterial
growth in the presence of colistin at 5 mg/liter was essentially
no different from that of the control with either inoculum (Fig.
3A and C).
Doripenem monotherapy. With ATCC 27853 at the 106-
CFU/ml inoculum, all doripenem regimens (2.5, 25, or 50 mg/
liter every 8 h) produced initial bacterial killing of 2.5 log10
CFU/ml, with regrowth beginning by 6 h (Fig. 2B). Regrowth
close to control levels had occurred by 48, 72, and 96 h with
concentrations of 2.5, 25, and 50 mg/liter, respectively. At the
high inoculum, all doripenem concentrations produced similar
killing profiles, with the 2.5-mg/liter 8-hourly regimen resulting
in bacterial counts consistently 0.5 to 1 log below control
values and the 25- and 50-mg/liter regimens yielding bacterial
counts 1.5 to 3 log below control values (Fig. 2E). With the
MDR isolate, doripenem at 2.5 mg/liter every 8 h produced
only minimal bacterial killing (1- to 2-log10 reduction in
CFU/ml) at each inoculum, with regrowth close to control
values by 24 to 48 h (Fig. 3A and C). Higher doripenem
concentrations (25 and 50 mg/liter) produced rapid initial kill-
ing of3 log at 6 h, with subsequent regrowth to within1 log
of control values at 96 h (Fig. 3A and C). No inoculum effect
was observed with doripenem against either strain.
Combination therapy. With ATCC 27853, the addition of
doripenem at 2.5 or 25 mg/liter to colistin at 0.5 mg/liter pro-
duced an initial (i.e., up to 8-h) period of additional bacterial
killing of 2.5 log10 CFU/ml compared with the most active
monotherapy (colistin) at the low inoculum and resulted in
undetectable bacterial counts no later than 3 h (Table 2). Both
combinations resulted in synergy or additivity at most time
points across 96 h (Table 2). Synergy was particularly evident
with the combination of colistin at 0.5 mg/liter and doripenem
at 2.5 mg/liter, with 3- to 4-log10-greater killing at most time
points. Nevertheless, by 96 h regrowth with this regimen ap-
proached that of the growth control. The addition of dorip-
enem (2.5 or 25 mg/liter) to colistin at 2 mg/liter produced
synergy at 48 and 72 h, and this combination remained additive
at 96 h with regrowth close to the level of the initial inoculum
(Fig. 2C and Table 2). At the high inoculum, combinations of
colistin at 0.5 mg/liter and doripenem (2.5 or 25 mg/liter)
produced only modest increases in bacterial killing across the
first 8 to 24 h, with regrowth thereafter similar to that in the
presence of the most active single agent (doripenem) (Fig.
2F). With combinations containing colistin at 2 mg/liter,
rapid and substantial reductions in bacterial counts were
observed, with additional killing of 3.5 log10 CFU/ml over
that achieved with the most active monotherapy at 8 h for
the combination with doripenem at 2.5 mg/liter and addi-
tional killing of 5 log10 CFU/ml achieved at 4 h for the
combination with doripenem at 25 mg/liter; with the latter
combination, no viable bacteria were detected at 4 h. Syn-
ergy or additivity was maintained with these combinations
across 48 and 96 h with doripenem at 2.5 and 25 mg/liter,
respectively (Table 2).
FIG. 3. Time-kill curves for colistin and doripenem monotherapy (A and C) and combination therapy (B and D) against 19147 n/m at the
106-CFU/ml inoculum (left panels) and the 108-CFU/ml inoculum (right panels). The y axis starts from the limit of detection, and the limit of
quantification (LOQ) is indicated by the horizontal broken line.
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Against 19147 n/m at the 106-CFU/ml inoculum, colistin at
0.5 mg/liter plus doripenem at 2.5 mg/liter produced synergy at
24 and 48 h, with regrowth approaching control values by 72 to
96 h (Fig. 3B and Table 2). A similar killing profile was gen-
erated with the combination of colistin at 2 mg/liter and dorip-
enem at 2.5 mg/liter, although initial bacterial killing was
greater (by 3 logs) and lower bacterial counts were main-
tained across the first60 h (Fig. 3B). With the latter regimen,
bacterial counts as low as 1.6 log10 CFU/ml (at 29 h) were
observed. With combinations containing colistin (0.5 or 2 mg/
liter) and doripenem at 25 mg/liter, the initial rate and extent
of killing up to 4 to 6 h were similar to those with doripenem
monotherapy (Fig. 3B). By 8 and 24 h, no viable bacteria were
observed with the combinations containing colistin at 2 and 0.5
mg/liter, respectively, and no regrowth was subsequently de-
tected. At the high inoculum, the combination of colistin at 0.5
mg/liter and doripenem at 2.5 mg/liter was essentially inactive
(Fig. 3D). Increasing the concentration of colistin to 2 mg/liter
produced greater bacterial killing at both 24 h (additive) and
48 h (synergistic), with regrowth to control levels by 72 h (Fig.
3D and Table 2). Substantially greater killing was observed
with combinations containing doripenem at 25 mg/liter. The
addition of doripenem at 25 mg/liter to colistin (0.5 or 2 mg/
liter) produced substantial reductions in log10 CFU/ml com-
pared to the equivalent doripenem monotherapy by 8 h (with
colistin at 2 mg/liter) and 29 h (with colistin at 0.5 mg/liter)
(Fig. 3D). No viable bacteria were detected at 50 h with both
combinations, with regrowth at 96 h substantially below (by
3.5 to 5 log10 CFU/ml) that occurring with equivalent dorip-
enem monotherapy (Fig. 3D).
Emergence of colistin resistance. Apart from a small shift to
the right from 0 to 96 h at the 106-CFU/ml inoculum, the PAPs
for ATCC 27853 at 96 h closely matched those observed at
baseline at both inocula. With this strain, a small number of
colistin-resistant colonies were detected at baseline at the high
inoculum and for both inocula following 96 h of incubation in
the model (Table 3). Colistin at 0.5 or 2 mg/liter resulted in
substantial increases in the proportion of colistin-resistant sub-
populations at both inocula (Fig. 4 and Table 3). With colistin
at 5 mg/liter, the substantially lower growth at 96 h (4.3 log10
CFU/ml) using an initial inoculum of 106 CFU/ml makes com-
parison of the PAPs at this time point difficult. However, at the
108-CFU/ml inoculum, a substantial increase in colistin-resis-
tant subpopulations was evident by 24 h with 5-mg/liter colistin
monotherapy (Fig. 3 and Table 3). For 19147 n/m, the PAPs at
baseline and across the 96 h of incubation did not change,
irrespective of the inoculum or colistin treatment (data not
shown).
Combination therapy against ATCC 27853 substantially re-
duced the emergence of colistin-resistant subpopulations (Ta-
ble 3). When doripenem at 2.5 mg/liter was added to colistin
(0.5 or 2 mg/liter) at both inocula, a small shift to the right in
the PAPs from 72 to 96 h was generally observed (Fig. 4). The
emergence of colistin-resistant subpopulations at both inocula
TABLE 2. Log changes in CFU/mla
a Log changes in CFU/ml at 6, 24, 48, 72, and 96 h at an inoculum of 106 or 108 CFU/ml with colistin (Col) and/or doripenem (Dor) against P. aeruginosa. The gray
background indicates activity (a reduction of 1-log10 CFU/ml below the initial inoculum); the green background indicates synergy (a 2-log10 decrease in the number
of CFU per milliliter with the combination compared to its most active component); the red background indicates additivity (a 1.0- to 2-log10 decrease in the number
of CFU per milliliter with the combination compared to its most active component). ††, colistin-heteroresistant reference strain. Heteroresistance to colistin was defined
as the ability of subpopulations of a strain to grow in the presence of 2 mg/liter although the colistin MIC for the strain was 2 mg/liter. ‡‡, nonmucoid MDR
colistin-resistant clinical isolate (colistin monotherapy was performed with 5 mg/liter only).
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was suppressed even further with the addition of doripenem at
25 mg/liter to colistin (0.5 or 2 mg/liter) (Fig. 4). For example,
with a starting inoculum of 108 CFU/ml, the combination of
colistin at 2 mg/liter plus doripenem at 2.5 mg/liter resulted in
substantially fewer colonies growing in the presence of 4
mg/liter colistin at 96 h than the equivalent colistin mono-
therapy (Fig. 4F). The number of resistant colonies was re-
duced even further with the combination of colistin at 0.5
mg/liter plus doripenem at 25 mg/liter, despite similar levels of
growth at this time point with all three regimens. Combination
therapy had no effect on colistin resistance of the MDR colis-
tin-resistant isolate (data not shown).
DISCUSSION
Colistin is increasingly used as salvage therapy in critically ill
patients for otherwise untreatable MDR infections (15, 27).
However, regrowth of colistin-susceptible P. aeruginosa with
colistin (or polymyxin B) monotherapy is commonly observed
(4, 10, 18, 22, 51), even with colistin concentrations well above
those which can be safely achieved clinically. In addition, re-
cent population PK studies employing currently recommended
CMS dosage regimens indicate that the plasma colistin con-
centrations achieved in critically ill patients are in many cases
suboptimal (16, 47). Given the potential for the rapid emer-
gence of colistin resistance with monotherapy, combination
therapy against P. aeruginosa has been suggested as a possible
means by which to increase antimicrobial activity and reduce
the development of resistance (29). We systematically investi-
gated the effectiveness of colistin alone and in combination
with doripenem against a colistin-heteroresistant strain and an
MDR colistin-resistant isolate of P. aeruginosa. Doripenem
was chosen because of its high potency against MDR P. aerugi-
nosa (11, 38) and its low potential for selection of carbapenem-
resistant P. aeruginosa (19, 37, 49). As some data show that the
activity of colistin (10) and carbapenems alone (36) is attenu-
ated at high compared to low inocula, in the present study
experiments were conducted at both 106 and 108 CFU/ml;
the latter inoculum mimics the high bacterial densities found in
some infections.
The dosage regimens of colistin and doripenem used in the
present study were carefully chosen to reflect the plasma drug
concentration-time profiles achieved in critically ill patients.
Intravenous administration of CMS, the parenteral formula-
tion of colistin, results in average steady-state plasma colistin
concentrations of 2 to 3 mg/liter, with some patients achiev-
ing concentrations up to 10 mg/liter (16, 31, 47). As colistin
concentrations at steady state remain more or less constant
(16, 47), colistin was administered as a constant infusion. We
have previously demonstrated that colistin is almost entirely
unbound in CAMHB (3). Thus, the colistin concentrations of
0.5 and 2 mg/liter used in our study are clinically achievable,
assuming plasma binding of colistin in patients is similar to that
in animals (i.e., 50% is bound) (25). Unfortunately, although
the knowledge of total plasma colistin concentrations achieved
in patients is increasing, there is currently no information on
unbound plasma colistin concentrations in humans. Though
the majority of PK data on doripenem have been obtained with
healthy volunteers, plasma drug concentration-time profiles
for patients appear to be similar to those for healthy volunteers
(39). Doripenem is typically administered intermittently every
8 h, with a standard 500-mg dose achieving a Cmax of 25
mg/liter (7, 42). As binding of doripenem in the growth me-
dium was minimal, all doripenem concentrations employed in
the combinations are readily achieved in plasma after consid-
eration of protein binding (7, 14, 20, 42).
To our knowledge, this is the first study to investigate the
combination of colistin plus doripenem against P. aeruginosa
using an in vitro PD model and to utilize colistin PK data
recently obtained from critically ill patients (discussed below).
An inoculum effect was generally observed for colistin mono-
therapy, whereas no obvious inoculum effect was present for
doripenem (Fig. 2 and 3). The addition of doripenem to colis-
tin resulted in substantial improvements in bacterial killing
over equivalent monotherapy against the MDR colistin-resis-
tant isolate at both inocula, particularly with a doripenem
TABLE 3. Proportions of colistin-resistant subpopulations of P. aeruginosa ATCC 27853 at various times in the in vitro PK/PD model
Inoculum
(CFU/ml)
Time
(h)
Proportion of subpopulations resistant to 4 mg/liter colistin with treatment regimen:
Control Col at 0.5mg/liter
Col at 2 mg/
liter
Col at 5 mg/
liter
Col at 0.5
mg/liter 
Dor at 2.5
mg/liter
Col at 0.5
mg/liter 
Dor at 25
mg/liter
Col at 2 mg/
liter  Dor at
2.5 mg/liter
Col at 2 mg/
liter  Dor at
25 mg/liter
106 0 NDa ND ND ND ND ND ND ND
6 ND ND ND ND ND ND ND ND
24 ND 3.08 
 101 ND ND ND ND ND ND
48 ND 2.82 
 101 ND ND ND ND 1.12 
 103 ND
72 ND 1.80 
 102 8.58 
 103 ND ND ND 2.67 
 103 ND
96 ND 3.67 
 102 7.37 
 101 ND 1.83 
 105 ND 1.75 
 105 8.78 
 105
108 0 1.19 
 107 1.72 
 107 ND 4.05 
 107 3.51 
 107 9.60 
 107 4.43 
 107 7.38 
 106
6 5.81 
 108 1.75 
 105 3.67 
 105 ND ND ND ND ND
24 1.01 
 107 8.22 
 106 1.25 
 101 1.29 
 102 ND ND ND ND
48 1.83 
 107 4.90 
 103 2.65 
 101 8.74 
 101 3.70 
 106 2.51 
 105 4.57 
 105 ND
72 2.95 
 108 3.18 
 103 3.01 
 101 9.49 
 101 3.14 
 104 ND 4.77 
 103 ND
96 8.92 
 108 3.22 
 103 2.72 
 101 9.71 
 101 7.78 
 104 5.66 
 105 6.55 
 103 ND
a ND, no colistin-resistant subpopulations detected.
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concentration of 25 mg/liter. Though the benefits in overall
antibacterial activity with the combination were slightly less
pronounced against the colistin-susceptible but -heteroresis-
tant strain, combination regimens nevertheless resulted in sub-
stantial improvements in bacterial killing, particularly with
combinations containing colistin at 2 mg/liter. Overall, our
data suggest that the addition of doripenem to even low con-
centrations of colistin (e.g., 0.5 mg/liter) can substantially im-
prove antibacterial activity. Given the current last-line status of
colistin therapy, we have reported not only synergy but also
additivity, as even a relatively small increase in activity with
clinically achievable concentrations of both antibiotics may be
beneficial to patient care.
Previous studies employing static time-kill methods have
examined colistin in combination with a carbapenem (imi-
penem, meropenem, or doripenem) against P. aeruginosa, with
mixed results (2, 5a, 12, 43, 44). In these previous studies,
investigations were undertaken for no longer than 48 h (usually
24 h) with a single dose of each antibiotic administered at the
commencement of treatment. Of these studies, only our pre-
vious study employed multiple inocula and investigated the
emergence of colistin resistance (5a); that study included both
FIG. 4. PAPs of ATCC 27853 with colistin monotherapy, colistin-plus-doripenem combination therapy, or neither antibiotic (control) at the
106-CFU/ml inoculum (left panels) and the 108-CFU/ml inoculum (right panels) at 24 h (A and B), 72 h (C and D), and 96 h (E and F). Baseline
(0-h) PAPs are shown in all panels. Colonies growing on 4 mg/liter colistin are considered resistant. The y axis starts from the limit of detection,
and the limit of quantification (LOQ) is indicated by the horizontal broken line.
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isolates used in the present study. While concentrations of
antibiotics in that study and the present study are not directly
comparable and the former study examined colistin in combi-
nation with imipenem, the activities of colistin combined with
either imipenem or doripenem were similar across 48 h (the
duration of the former study) at both inocula of ATCC 27853.
However, substantial differences against the MDR colistin-
resistant isolate were evident. In the static model, combina-
tions with concentrations as high as 32 mg/liter colistin plus
imipenem at 16
 MIC failed to reduce bacterial numbers to
below the limit of detection at any time point. In stark contrast,
bacterial eradication was achieved in the PK/PD model with
combinations containing colistin (0.5 or 2 mg/liter) and dorip-
enem at 25 mg/liter no later than 24 h at the low inoculum, and
bacteria were reduced to below detectable levels at approxi-
mately 48 h with the same combinations at the high inoculum.
This highlights the importance of simulating PK profiles when
examining PD responses.
Though P. aeruginosa can undergo adaptive resistance to
polymyxins (17), the report of colistin heteroresistance in P.
aeruginosa (5a) and changes in PAPs following treatment
with colistin monotherapy (4, 5a, 10) suggest that amplifi-
cation of preexisting colistin-resistant subpopulations is a
contributing factor in the regrowth observed with colistin
monotherapy. This pattern was similarly observed in the
present study with colistin monotherapy. Though the mean-
ingful interpretation of PAPs is difficult when combination
therapy has led to extensive killing, an important finding of
the present study is that when bacterial numbers were com-
parable (within 1 to 2 log10 CFU/ml of those achieved with
the equivalent monotherapy), combination therapy against
the colistin-heteroresistant strain at both inocula substan-
tially reduced and delayed the emergence of colistin-resis-
tant subpopulations. Whereas colistin-resistant colonies
emerged rapidly (often within 24 h) with colistin mono-
therapy, with combination therapy resistant colonies gener-
ally emerged later (following 72 to 96 h of treatment) and
formed a substantially smaller proportion of the overall
bacterial population (Table 3). In addition, the most resis-
tant subpopulations (i.e., those growing in the presence of
colistin at 10 mg/liter on the PAP plates) were absent with
combination therapy. In contrast, we previously reported
that changes in the PAPs with colistin and imipenem com-
bination therapy in a static time-kill model generally mir-
rored those observed with equivalent exposure to colistin
monotherapy (5a). Loss of imipenem due to degradation in
the static experiments likely contributed to this result (21).
Intermittent dosing of doripenem in the present study re-
plenishes doripenem concentrations and avoids the combi-
nation’s effectively becoming colistin monotherapy over
time. This reported difference highlights once again the
importance of PK/PD models in assessing the activity of and
the emergence of resistance to antimicrobial therapy.
We have previously suggested two possible reasons for an
enhanced PD effect observed with the combination of colis-
tin and a carbapenem (9). Subpopulation synergy involves
one drug killing the subpopulation(s) resistant to the other
drug and vice versa. ATCC 27853 is colistin heteroresistant,
indicating the existence of colistin-resistant subpopulations
prior to therapy. Though regrowth of this strain occurred
with all combinations, it was considerably reduced with com-
binations containing each drug at the higher concentration,
particularly over the first 48 to 72 h. Interestingly, high-level
colistin resistance did not emerge despite the regrowth.
While subpopulation synergy may have contributed to an
enhanced PD effect against this isolate, it cannot explain the
substantially enhanced activity of colistin-doripenem com-
binations against the MDR colistin-resistant isolate given its
near complete resistance to colistin (MIC, 128 mg/liter).
This enhanced activity occurred despite the presence of
enzymes active against carbapenems. Mechanistic synergy
involves colistin and doripenem acting on different cellular
pathways to increase the rate or extent of killing by the other
drug. It is possible that permeabilization of the outer mem-
brane by colistin (56) resulted in substantially increased
concentrations of doripenem in the periplasm, allowing
greater access to the critical penicillin-binding proteins lo-
cated on the cytoplasmic membrane where the carbapenems
act (41, 54). Subpopulation and mechanistic synergies are
not mutually exclusive, and both may operate simultane-
ously. Further investigations are ongoing to elucidate the
mechanism(s) underpinning the enhanced PD activity ob-
served.
We have shown for the first time that clinically relevant
dosage regimens of colistin and doripenem in combination
substantially increase killing of both colistin-susceptible (and
-heteroresistant) and MDR colistin-resistant P. aeruginosa,
even at a high initial inoculum. Combination therapy also sub-
stantially reduced and delayed the emergence of colistin resis-
tance. Our data highlight the importance of prospective opti-
mization of colistin combinations using a translational PK/PD
approach. Further investigations of colistin combinations in
animal infection models and patients are warranted to opti-
mize colistin-doripenem combinations targeting isolates which
are resistant to all antibiotics, including the last-line therapy
colistin.
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